Severe fever with thrombocytopenia syndrome (SFTS), caused by a novel identified bunyavirus SFTS virus (SFTSV), was an emerging viral infectious disease that was firstly reported in China. There are no licensed vaccines and therapeutics against SFTSV currently. B-Propiolactone (BPL) inactivated whole virions of SFTSV strain AH12 were prepared as experimental vaccine in different antigen dose with or without Al(OH) 3 adjuvant. The experimental SFTS vaccine was a satisfying immunogen, which could efficiently trigger the development of high levels of SFTSV NP-specific IgG antibodies and neutralizing antibodies against SFTSV Strain HB29 in BALB/c and C57/BL6 mice, and could induce SFTS virus-specific cellular immune responses to a certain extent. A single dose of vaccine was immunogenically insufficient in BALB/c mice; the second and third dose resulted in significant boost in antibody response. The use of Al(OH) 3 adjuvant resulted in higher antibody titers. The mediate-dose of vaccine could induce as high and equivalent level of antibody titer as that of high-dose. The experimental SFTS vaccine in mediate-and high antigen dose with adjuvant resulted in solid protection of C57/BL6 mice against wild-type SFTSV challenge with markedly accelerated virus clearance from blood and spleen compared with controls. The experimental SFTS vaccine prepared in this study could efficiently elicit virus specific humoral and cellular immune responses in both BALB/c and C57/BL6 mice, and could protect C57/BL6 mice against SFTS virus challenge. These results supplied evidence that inactivated vaccine was a promising vaccine candidate for the prevention of SFTSV infection.

SFTS virus;Inactivated vaccine;Immunogenicity;Protective efficacy

Li Aqian;Dai Xinxian;Chen Lei;Liu Lin;Li Chuan;Liu Yang;Wu Wei;Huang Xiaoxia;Li Jiandong;Wang Shiwen;Liang Mifang;Li Xiuling;Li Dexin

Department of Viral Hemorrhagic Fever, National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China;National Vaccine and Serum Institute, Beijing 102206, China;Suzhou Institute of Systems Medicine, Suzhou 215123, China;China CDC-WIV Joint Research Center for Emerging Diseases and Biosafety, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China

生物安全与健康 （英文）

[1]Li Aqian;Dai Xinxian;Chen Lei;Liu Lin;Li Chuan;Liu Yang;Wu Wei;Huang Xiaoxia;Li Jiandong;Wang Shiwen;Liang Mifang;Li Xiuling;Li Dexin-.Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice)[J].生物安全与健康 （英文）,2022(01):45-52

Propiolactone,AH12,HB29,immunogenically,Inactivated

Immunogenicity,protective,efficacy,inactivated,candidate,mice,Severe,fever,thrombocytopenia,syndrome,caused,by,novel,identified,bunyavirus,SFTSV,was,emerging,viral,infectious,disease,that,firstly,reported,China,There,licensed,vaccines,therapeutics,against,currently,BPL,whole,virions,strain,were,prepared,experimental,different,antigen,dose,without,adjuvant,satisfying,which,could,efficiently,trigger,development,levels,NP,specific,IgG,antibodies,neutralizing,Strain,BALB,C57,BL6,induce,cellular,immune,responses,certain,extent,single,insufficient,second,third,resulted,significant,boost,antibody,higher,titers,mediate,equivalent,solid,protection,wild,type,challenge,markedly,accelerated,clearance,from,blood,spleen,compared,controls,this,study,elicit,humoral,both,These,results,supplied,evidence,promising,prevention,infection,Protective

0.423653